<unk>  is an alkylating drug that is FDA approved for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.   Common adverse reactions include nausea, fatigue, vomiting, constipation, decreased appetite, diarrhea, peripheral edema, dyspnea, and headache (≥20%).
Trabectedin
Temoporfin
Verteporfin
Dalcetrapib
Vicriviroc
Diprenorfin
Niraparib
Etravirine